Elite in Defective Apolipoprotein B-100

Gerald F. Watts

35 Stirling Highway, 
Nedlands, WA, AU 
Elite in Defective Apolipoprotein B-100
35 Stirling Highway, 
Nedlands, WA, AU 
OverviewLocationsClinical Research

Overview

Gerald Watts practices in Nedlands, Australia. Mr. Watts is rated as an Elite expert by MediFind in the treatment of Defective Apolipoprotein B-100. His top areas of expertise are Familial Hypercholesterolemia, High Cholesterol, Homozygous Familial Hypercholesterolemia (HoFH), and Familial Hypertriglyceridemia.

His clinical research consists of co-authoring 874 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 210 articles and participated in 2 clinical trials in the study of Defective Apolipoprotein B-100.

Gender
Male

Locations

35 Stirling Highway, Nedlands, WA 6009, Australia
Other Locations
197 Wellington Street, Perth, WA 6000, Australia
35 Stirling Hwy, Crawley, WA 6009, Australia
Level 4, Rear 50 Murray Street, Perth, WA 6000, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase 2 Study to Evaluate the Safety and Efficacy of ARO-ANG3 in Subjects With Homozygous Familial Hypercholesterolemia (HOFH)
Phase 2 Study to Evaluate the Safety and Efficacy of ARO-ANG3 in Subjects With Homozygous Familial Hypercholesterolemia (HOFH)
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: ARO-ANG 3
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Enrollment Status: Completed
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drug: ARO-APOC3
Study Phase: Phase 2
A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults With Dyslipidemia
A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults With Dyslipidemia
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drug: ARO-APOC3
Study Phase: Phase 3
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia
Enrollment Status: Completed
Publish Date: November 07, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double Blind, Placebo Controlled, Multicenter, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of HTD1801 in Adults With Hypercholesterolemia
A Randomized, Double Blind, Placebo Controlled, Multicenter, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of HTD1801 in Adults With Hypercholesterolemia
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients
A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients
Enrollment Status: Completed
Publish Date: September 21, 2021
Intervention Type: Drug
Study Drug: ARO-ANG3
Study Phase: Phase 1
A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as Well as in Severely Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome
A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as Well as in Severely Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome
Enrollment Status: Completed
Publish Date: March 03, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

873 Total Publications

Female Specific Risk of Pancreatitis in Severe Hypertriglyceridemia: Implications for Family Planning and New Guidelines.
Female Specific Risk of Pancreatitis in Severe Hypertriglyceridemia: Implications for Family Planning and New Guidelines.
Journal: The Journal of clinical endocrinology and metabolism
Published: August 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Watts's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 9 Advanced Conditions
View All 27 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile